Home> Industry News > All

Chinese researchers report first lung stem cell transplantation clinical trial

clinical trialsworldpharmanews2018-02-11 17:22Read   4

A research team from Tongji University in China have made a breakthrough in human lung regeneration technology. For the first time, researchers have regenerated patients' damaged lungs using autologous lung stem cell transplantation in a pilot clinical trial. The study can be found in the open access journal Protein & Cell which is published by Springer Nature.

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Commentspmlive2018-02-11 17:18Read   4

Boehringer Ingelheim’s Ofev subject to same conditions

Novartis' Sandoz Jobs on the Chopping Block

TrendBiospace2018-02-11 09:23Read   3

The first of the pink slips at Sandoz’ generic-drug manufacturing facility in Broomfield, Colo. have been handed out. The company issued 65 layoff notices this week, BizWest reported, citing a WARN notice filed with the Colorado Department of Labor and Employment.

FDA hands GSK a reprieve by blocking Novartis generic

Trendpmlive2018-02-11 09:20Read   2

GlaxoSmithKline could reach the end of 2018 without generic competition to its big-selling Advair respiratory drug in the US, after the FDA rejected Novartis’ rival.

Sarepta contains UK study halt, for now

TrendEPVantage2018-02-11 09:20Read   1

Sarepta made a neat transition from its marketed Duchenne muscular dystrophy drug, Exondys 51, to developing what could be an even better asset, golodirsen. But there could be trouble ahead: treatment at UK sites involved in the latter’s pivotal trial has just been halted, EP Vantage has learned.

'Soft' chemotherapy effective in older patients when added to targeted treatment in aggressive breast cancer subtype

clinical trialsEORTC2018-02-11 09:16Read   2

Avoidance of side-effects of chemotherapy is particularly important in the elderly, but finding the balance between reduced toxicity and maximum effectiveness is not always easy.

AstraZeneca’s Brilinta shows benefits for heart attack patients in phase III trial

clinical trialsAstraZeneca2018-02-11 09:16Read   5

AstraZeneca’s Brilinta significantly reduced cardiovascular (CV) events and coronary death beyond one year in heart attack survivors with multi-vessel disease in a Phase III trial.

Two Drugs (#Apalutamide and #Enzalutamide) Offer Hope Against a Tough-to-Treat Prostate Cancer

clinical trialsDrugs2018-02-11 08:55Read   1

Two cancer drugs can stall the progression of a particularly hard-to-treat form of prostate cancer, a pair of new trials shows.

Teva Migraine Drug Likely Delayed by Manufacturing Trouble

Trendxconomy2018-02-09 09:13Read   2

Teva Pharmaceutical’s bid to bring a new migraine drug to the market faces a possible delay due to manufacturing problems found with one of the company’s partners, and observers are skeptical about whether Teva will be able to get it over the finish line.

Roche purchases shares in tender offer for Ignyta, Inc.

Trendworldpharmanews2018-02-09 09:11Read   3

Roche and Ignyta, Inc. today announced that Roche's wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Ignyta, Inc

ASCO GU 2018: Genetic gene mutations: opening new therapeutic avenues in metastatic prostate cancer

TrendASCO GU 20182018-02-09 09:08Read   2

The study showing for the first time that patients with inherited DNA repair mutations benefit from standard therapies in a similar way to other metastatic prostate cancer patients.

Janssen to co-develop Theravance's TD-1473 in $1bn deal

TrendPBR2018-02-09 09:08Read   2

Janssen Biotech will co-develop Theravance’s TD-1473 and associated backup compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease, through an agreement that is potentially worth about $1bn.

First Prev 1 2 3 4 Next Last GO
You may interest
Insert title here
Feed-Back To Top
ICP Permit 14047345| Beijing PSB Hai Dian Record 11010802017043 |(京)-经营性-2015-0023(互联网药品信息服务资格证书)
Insert title here
Feed-Back To Top